89bio Inc (ETNB)
8.98
+0.01
(+0.11%)
USD |
NASDAQ |
May 20, 16:00
9.13
+0.15
(+1.67%)
After-Hours: 20:00
89bio Cash from Operations (TTM): -138.82M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -138.82M |
December 31, 2023 | -129.19M |
September 30, 2023 | -121.99M |
June 30, 2023 | -106.44M |
March 31, 2023 | -86.83M |
December 31, 2022 | -81.09M |
September 30, 2022 | -82.23M |
June 30, 2022 | -80.87M |
March 31, 2022 | -86.14M |
Date | Value |
---|---|
December 31, 2021 | -76.78M |
September 30, 2021 | -62.57M |
June 30, 2021 | -62.06M |
March 31, 2021 | -53.47M |
December 31, 2020 | -46.24M |
September 30, 2020 | -43.35M |
June 30, 2020 | -36.60M |
March 31, 2020 | -29.04M |
December 31, 2019 | -25.46M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-138.82M
Minimum
Mar 2024
-25.46M
Maximum
Dec 2019
-74.96M
Average
-78.82M
Median
Cash from Operations (TTM) Benchmarks
Akero Therapeutics Inc | -155.88M |
Madrigal Pharmaceuticals Inc | -389.32M |
Viking Therapeutics Inc | -54.87M |
Galectin Therapeutics Inc | -34.28M |
Terns Pharmaceuticals Inc | -75.81M |